More

• Abbott & Boston Scientific: Rising Stent Stars Wednesday, 17 Sep 2008 | 12:21 PM ET

  

  Not too long ago, some had written off the potential for significant growth to resume in sales of the little wire mesh tubes that are painted with special drugs to help keep arteries from reclogging.

• Amgen's Embargo Victory Tuesday, 16 Sep 2008 | 12:30 PM ET

  

  This morning the world's biggest biotech company released the highly-anticipated detailed test results on its crucial, late-stage experimental osteoporosis drug known as D-mab. And they look good.

• Putting My Finger On The BlackBerry Addiction Friday, 12 Sep 2008 | 2:03 PM ET

  

  Yesterday afternoon I became a statistic. I am now among the reportedly growing number of people getting injured while texting and--not driving--but walking.

• ImClone-Bristol Battle Is Really Gettin' Good Friday, 12 Sep 2008 | 9:57 AM ET

  

  I finished my last ImClone Systems vs. Bristol-Myers Squibb entry asking what Bristol had to say about IMCL's claim of a mystery outbidder. Well, yesterday we found out in a press release from BMY.

• Charts Point to European Drug Stocks Thursday, 11 Sep 2008 | 7:56 AM ET

  Of all the places to put money to work in Europe, the pharmaceutical sector is the most promising, a technical analyst told CNBC Thursday.

• ImClone's Icahn: Holding A Pistol To Bristol Wednesday, 10 Sep 2008 | 12:05 PM ET

  

  At the Thomson Reuters/BioCentury investment conference some hedge fund guy, who I'd never met before and who will remain unidentified, whispered in my ear that there's gonna be a bidding war for ImClone Systems.

• Pfizer: A Delay And A Deal? Tuesday, 9 Sep 2008 | 12:06 PM ET

  At the risk of getting more emails from conspiracy-theorist readers who think I report too much negative news about Pfizer, here comes another setback for the world's biggest drug company.

• Fannie, Freddie & Pharma: Resolution "Helps" Sector Stocks? Monday, 8 Sep 2008 | 11:17 AM ET

  

  John Sullivan, the Director of Research at Lerrink Swann, which specializes in healthcare stocks, says there is a potential trading opportunity in the sector related to F & F.

• Lilly's Brewing Battle With Bristol And Your Emails Friday, 5 Sep 2008 | 12:58 PM ET

  

  Earlier this week I blogged about Eli Lilly's "Coming Soon" banner ad I spotted in the online edition of "The New England Journal of Medicine." It's designed to generate buzz about the company's crucial new bloodthinner that could win Food and Drug Administration approval this month.

• At The End Of The Day: Dendreon Thursday, 4 Sep 2008 | 4:30 PM ET

  

  Dendreonians, the wait is over. Dendreon had the second-to-last time slot at the BioCentury/Thomson Reuters biotech investment conference this afternoon.

• Celgene's Success Story Thursday, 4 Sep 2008 | 3:37 PM ET

  One of the biggest biotech success stories is among the companies featured in the afternoon sessions here at the BioCentury/Thomson Reuters investment conference.

• Amylin's Byetta Battle Thursday, 4 Sep 2008 | 12:26 PM ET

  Of the 36 companies presenting here at the BioCentury/Thomson Reuters biotech conference, investors are probably most interested in the update from Amylin Pharmaceuticals.

• Orexigen And Its Obesity Bets Thursday, 4 Sep 2008 | 11:51 AM ET

  

  After Medivation, I moved onto the Orexigen presentation. It's a company I profiled at when it had data on one of its fat-fighting drugs at last year's diabetes conference, so I wanted to check up on its progress.

• Medivation's Presentation Thursday, 4 Sep 2008 | 10:18 AM ET

  

  A little more than 24 hours after announcing its big, lucrative Alzheimer's drug partnership with Pfizer, Medivation had the lead-off position (I wonder if they told organizers they'd be a newsmaker) at today's BioCentury/Thomson Reuters biotech investment conference in New York City.

• Biotech Bonanza At Industry Conference Thursday, 4 Sep 2008 | 9:09 AM ET

  Today I will be attending and blogging from the 15th Annual Newsmakers in the Biotech Industry conference which is put on by BioCentury Publications and Thomson Reuters. Three dozen biotechs will be making presentations and then doing hour-long q and a's during breakout sessions.

• Where to Find Prescription Drugs For Less Wednesday, 3 Sep 2008 | 8:51 PM ET

  Cheaper medications await if you know where to look.

• Pfizer Finding Innovation At Medivation Wednesday, 3 Sep 2008 | 10:32 AM ET

  

  In late July at a big scientific conference in Chicago, I reported on new, positive data on Medivation's experimental Alzheimer's drug Dimebon (dim-uh-bahn).

• No Vindication For Vytorin; Victory for Sciele Tuesday, 2 Sep 2008 | 1:30 PM ET

  

  While I was on the "New England Journal of Medicine" Web site yesterday preparing my reports for today about the embargoed articles, I noticed a banner ad at the top of the homepage from Eli Lilly saying something along the lines of, "Coming Soon: Effient (Prasugrel)."

• For Widely Used Drug, Question of Usefulness Lingers Tuesday, 2 Sep 2008 | 4:51 AM ET

  

  When the Food and Drug Administration approved a new type of cholesterol-lowering medicine in 2002, it did so on the basis of a handful of clinical trials covering a total of 3,900 patients. None of the patients took the medicine for more than 12 weeks, and the trials offered no evidence that it had reduced heart attacks or cardiovascular disease, the goal of any cholesterol drug, the New Yor Times reported.

• Hurricane Lurking For Merck & Schering-Plough? Friday, 29 Aug 2008 | 11:34 AM ET

  

  This won't be much of an end-of-summer holiday weekend for the folks at Merck and Schering-Plough. That's because early Tuesday morning (5am ET) the detailed results of the so-called SEAS study will be presented at a scientific conference in Germany. This is the test of MRK and SGP's cholesterol drug Vytorin, which showed a higher incidence of cancer among the patients taking the pill.